Abstract 4707
Background
The NIVOREN GETUG-AFU 26 study reported safety and efficacy of N in mccRCC pts in a “real world setting”. A translationnal research program was launched to characterize immune cell populations in and around the tumor by immunohistochemistry (IHC) and correlate them with outcome on N.
Methods
All pts treated with N in the GETUG AFU 26 NIVOREN trial who consented for translational program and with available archived paraffin-embedded (FFPE) tumor tissue samples were eligible. Tumor were centrally reviewed. Densities of CD3-, CD8- and CD20-cells and tertiary lymphoid structures (TLS) were estimated by IHC. PD-L1 expression was quantified as percentage of positive tumor cells (TC) and immune cells (IC).
Results
Overall 324 pts were included. Pts had similar baseline characteristics (IMDC Good, Intermediate, Poor in 18%, 60% and 22%, respectively) than overall trial population. Median PFS was 4.5 (2.9-5.2) months and median OS 25.4 (23.6-NE) months. Highest density of CD8 T cells at the invasive margin (IM) was associated with worse PFS (2.3 vs 4.6 months, HR = 3.96 (1.84-8.51), p = 0.0001) and OS (8.6 vs 25.4 months, HR = 2.43 (0.99-5.95), p = 0.0451). PD-L1 expression on TC (³1%) was associated with worse OS (22.7 vs 29.1 months, HR = 1.51 (1.06-2.15), p = 0.0232) but not PFS (3.5 vs 4.6 months, p = 0.5121). PD-L1 expression on IC (³1%) was associated with numerically shorter median OS (24.7 months vs NR, HR = 1.34 (0.95-1.88), p = 0.0955). CD8 densities, either in the T or at the IM were associated with high PD-L1 expression (>1%) by TC or by IC (all p < 0.0001). Densities of CD3, CD20 and TLS were not significantly associated with OS or PFS. More data such as response rates and combinations of markers will be presented at the meeting.
Conclusions
We report the largest translational analysis supporting that highest CD8 density at the IM is associated with worse OS and PFS while PD-L1 expression by ³1% TC or IC is associated with worse OS in pts with mccRCC receiving N.
Clinical trial identification
NCT03013335.
Editorial acknowledgement
Legal entity responsible for the study
UNICANCER.
Funding
Institut National du Cancer, Direction Générale de l’Offre de Soins, Bristol-Myers-Squibb.
Disclosure
Y. Vano: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy: Pfizer; Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy: Merck; Travel / Accommodation / Expenses: Janssen-Cilag; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (self), Advisory / Consultancy: Astellas. N. Rioux-Leclercq: Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Janssen-Cilag; Honoraria (self), Advisory / Consultancy: Ipsen. B. Beuselinck: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): BMS. M. Gross-Goupil: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: GSK. S. Negrier: Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy: Eusa Pharma. D. Borchiellini: Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Janssen-Cilag; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas; Honoraria (self), Advisory / Consultancy: Sanofi. B. Escudier: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy: Eusa Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Aveo. L. Albiges: Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: Ipsen; Honoraria (institution), Advisory / Consultancy: Roche; Honoraria (institution), Advisory / Consultancy: MSD; Honoraria (institution), Advisory / Consultancy: AstraZeneca; Honoraria (institution), Advisory / Consultancy: Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
4145 - Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 countries
Presenter: Rachel Giles
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
Poster Discussion – Genitourinary tumours, non-prostate - Invited Discussant 904PD, 905PD and 906PD
Presenter: Joaquim Bellmunt
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Poster Discussion – Genitourinary tumours, non-prostate - Invited Discussant 907PD, 908PD, 909PD and 910PD
Presenter: Guillermo A. De Velasco Oria de Rueda
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Slides
Poster Discussion – Genitourinary tumours, non-prostate - Invited Discussant 911PD and 912PD
Presenter: Viktor Gruenwald
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Poster Discussion – Genitourinary tumours, non-prostate - Invited Discussant 913PD, 914PD and 915PD
Presenter: Christian Kollmannsberger
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast